GlassScriptPhysician profile
Susan E Weisman
NPI 1083060172
$3,400.16
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,803 · 2022: $561 · 2023: $968 · 2024: $67.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.01 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $1,650.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $220.85 | 2021-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $196.44 | 2023 | Lynparza, Imfinzi |
| Genzyme Corporation | $168.07 | 2022-2023 | |
| Amgen INC. | $162.96 | 2022-2023 | Kyprolis, Lumakras, Nplate |
| Genentech USA, INC. | $127.24 | 2022-2023 | Venclexta, Tecentriq |
| Mirati Therapeutics, INC. | $113.36 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $102.77 | 2021-2023 | |
| Janssen Biotech, INC. | $99.00 | 2023 | Darzalex |
| Lilly USA, LLC | $69.84 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $58.03 | 2023 | Epkinly, Imbruvica |
| Celgene Corporation | $35.22 | 2022 | |
| Daiichi Sankyo INC. | $33.50 | 2022-2023 | Enhertu |
| Gilead Sciences, INC. | $29.88 | 2022-2023 | Trodelvy |
| Myriad Genetic Laboratories, INC. | $27.52 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.03 | 2022-2023 | |
| Eisai INC. | $24.62 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.60 | 2022 | |
| Progenics Pharmaceuticals, INC. | $23.12 | 2023 | Pylarify |
| Puma Biotechnology, INC. | $22.30 | 2023 | Nerlynx |
| Glaxosmithkline, LLC. | $22.09 | 2022 | |
| Merck Sharp & Dohme LLC | $21.50 | 2023 | Keytruda |
| Pharmaessentia USA Corporation | $19.23 | 2023 | Besremi |
| Regeneron Healthcare Solutions, INC. | $18.59 | 2023 | Libtayo |
| Immunogen, INC. | $17.48 | 2023 | Elahere |
| Sumitomo Pharma America, INC. | $15.91 | 2023 | Orgovyx |
| Stemline Therapeutics INC. | $14.87 | 2023 | Orserdu |
| G1 Therapeutics, INC. | $14.73 | 2023 | Cosela |
| Blueprint Medicines Corporation | $12.97 | 2023 | Ayvakit |
| Kite Pharma, INC. | $12.85 | 2022 | |
| Kyowa Kirin, INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Weisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.